What imaging or biomarker tools help refine lipid management decisions beyond the lipid panel?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Beyond the standard lipid panel, imaging and biomarker tools give a deeper view of cardiovascular risk and help steer how aggressively to treat. The coronary artery calcium score uses a CT scan to detect calcified plaque, refining ASCVD risk especially in people with intermediate risk and helping decide whether to intensify or de-escalate lipid-lowering therapy. Lipid particle testing, including measurements of LDL particle number and apolipoprotein B, reveals the actual burden of atherogenic particles and can uncover residual risk or discordance with LDL-C, guiding decisions about adding non-statin therapies or adjusting targets. Measuring lipoprotein(a) identifies an independent, genetically driven risk factor that can elevate ASCVD risk even when LDL-C is controlled, potentially prompting more aggressive risk reduction or consideration of therapies that lower Lp(a) in the future. Together, these tools complement the lipid panel and refine how lipid management is personalized, making all of the above useful in practice.